Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

Background Nivolumab is an anti-PD-1 antibody approved for treating metastatic melanoma (MM), for which still limited evidence is available on the correlation between drug exposure and patient outcomes.Methods In this observational retrospective study, we assessed whether nivolumab concentration is...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Diana Giannarelli, Michael Bailey, Andrew White, Sandro Pignata, Corrado Caracò, Paolo Antonio Ascierto, Assunta Esposito, Lucia Festino, Alfredo Budillon, Sarah Warren, Domenico Mallardo, Paolo Muto, Antonella Petrillo, Vito Vanella, Ernesta Cavalcanti, Claudia Trojaniello, Maria Grazia Vitale, Giusy Trillò, Maria Antonietta Isgrò, Piera Maiolino, Domenico Galati, Grazia D'Angelo, Teresa De Cristofaro
Formaat: Artikel
Taal:English
Gepubliceerd in: BMJ Publishing Group 2022-11-01
Reeks:Journal for ImmunoTherapy of Cancer
Online toegang:https://jitc.bmj.com/content/10/11/e005132.full

Internet

https://jitc.bmj.com/content/10/11/e005132.full

Gelijkaardige items